Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697819 | Clinical Oncology | 2017 | 8 Pages |
Abstract
Based on the current available evidence, SRS alone was found to be cost-effective for patients with one to three brain metastases compared with upfront WBRT plus SRS.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H. Kim, M.S. Rajagopalan, S. Beriwal, K.J. Smith,